Andrew Witty, formerly CEO of drug giant GlaxoSmithKline, is now a member of the board of directors at RTP-based G1 Therapeutics.

The company, which is developing therapies to fight cancer, recently went public for more than $100 million. Two candidates are under clinical development.

Witty retired from GSK earlier this year. He currently is chancellor of the University of Nottingham in England.

“We are thrilled to welcome Andrew to our board of directors,” said Mark Velleca, G1 Therapeutics’s CEO, in the announcement, which was made Thursday.

“Andrew led and oversaw the development, commercialization, and global market access for several leading pharmaceutical products at GSK. We anticipate leveraging his wealth of industry experience as we advance G1’s portfolio of potential best-in-class and first-in-class therapies.”

In a statement, Witty said he sees promise in G1’s oncology candidates.

“As someone who is passionate about the development of new and meaningful medicines, I am delighted to join the G1 board of directors,” Witty said. “The encouraging early clinical data generated by G1’s CDK4/6 inhibitors support their potential to improve patient outcomes in multiple oncology indications. I look forward to working with the G1 team at this exciting time of corporate growth.”